HRP20100725T1 - Derivati ksantina kao selektivni agonisti hm74a - Google Patents
Derivati ksantina kao selektivni agonisti hm74a Download PDFInfo
- Publication number
- HRP20100725T1 HRP20100725T1 HR20100725T HRP20100725T HRP20100725T1 HR P20100725 T1 HRP20100725 T1 HR P20100725T1 HR 20100725 T HR20100725 T HR 20100725T HR P20100725 T HRP20100725 T HR P20100725T HR P20100725 T1 HRP20100725 T1 HR P20100725T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- intended
- compound
- treatment
- dyslipidemia
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 18
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VEEPFOJGVUXDRX-UHFFFAOYSA-N 3-butyl-8-chloro-1-[3-[5-[(4-fluorophenyl)methyl]tetrazol-2-yl]propyl]-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C=2N=C(Cl)NC=2C(=O)N1CCCN(N=1)N=NC=1CC1=CC=C(F)C=C1 VEEPFOJGVUXDRX-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- -1 fibrates Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
PCT/EP2006/007865 WO2007017261A1 (en) | 2005-08-10 | 2006-08-08 | Xanthine derivatives as selective hm74a agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100725T1 true HRP20100725T1 (hr) | 2011-01-31 |
Family
ID=37189397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100725T HRP20100725T1 (hr) | 2005-08-10 | 2010-12-27 | Derivati ksantina kao selektivni agonisti hm74a |
Country Status (29)
Country | Link |
---|---|
US (3) | US20100179128A1 (de) |
EP (3) | EP1912991B1 (de) |
JP (2) | JP5112316B2 (de) |
KR (2) | KR20080038396A (de) |
AR (1) | AR055369A1 (de) |
AT (1) | ATE487719T1 (de) |
AU (2) | AU2006278215A1 (de) |
BR (2) | BRPI0614270A2 (de) |
CA (2) | CA2618963A1 (de) |
CR (2) | CR9749A (de) |
CY (1) | CY1111757T1 (de) |
DE (1) | DE602006018151D1 (de) |
DK (1) | DK1912991T3 (de) |
EA (2) | EA200800564A1 (de) |
ES (1) | ES2401128T3 (de) |
HK (1) | HK1116779A1 (de) |
HR (1) | HRP20100725T1 (de) |
IL (2) | IL189081A0 (de) |
MA (2) | MA29692B1 (de) |
MX (2) | MX2008001931A (de) |
MY (1) | MY142067A (de) |
NO (2) | NO20081211L (de) |
NZ (1) | NZ565494A (de) |
PE (1) | PE20070405A1 (de) |
PL (1) | PL1912991T3 (de) |
PT (1) | PT1912991E (de) |
SI (1) | SI1912991T1 (de) |
TW (1) | TW200800217A (de) |
WO (2) | WO2007017261A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
DK1781657T3 (da) * | 2004-02-14 | 2013-06-10 | Glaxosmithkline Ip Dev Ltd | Medikamenter med hm74a-receptor aktivitet |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
NZ565494A (en) * | 2005-08-10 | 2011-06-30 | Glaxosmithkline Llc | Xanthine derivatives as selective HM74A agonists |
WO2007150026A2 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
EP2044074A2 (de) | 2006-06-23 | 2009-04-08 | Incyte Corporation | Purinonderivate als hm74a-agonisten |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
RS53777B1 (en) | 2008-12-08 | 2015-06-30 | Glaxosmithkline Llc | 8-CHLORO-3-PENTYL-3,7-DIHYDRO-1H-PURIN-2,6-DION 2-AMINO-2- (HYDROXYMETHYL) -1,3-PROPANDIOL ANHYDRID FOR DISEASE TREATMENT |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
SG187549A1 (en) * | 2010-08-16 | 2013-03-28 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
JP5828188B2 (ja) * | 2010-09-23 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のオキサジアゾール阻害剤 |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (de) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren |
SG11201406890YA (en) * | 2012-05-30 | 2014-11-27 | Hoffmann La Roche | Triazolo compounds as pde10 inhibitors |
JP6360149B2 (ja) * | 2013-03-15 | 2018-07-18 | ハイドラ バイオサイエンシズ インコーポレイテッドHydra Biosciences,Inc. | 置換キサンチンおよびその使用方法 |
EA030942B1 (ru) | 2013-05-10 | 2018-10-31 | Джилид Аполло, Ллс | Ингибиторы акк и их применение |
BR112015028214A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
JP6417402B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
JP6417401B2 (ja) * | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
CN104211702B (zh) * | 2013-05-29 | 2018-08-31 | 中国医学科学院药物研究所 | 取代黄嘌呤类化合物及其制备方法和用途 |
CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
CN114874209A (zh) * | 2017-03-07 | 2022-08-09 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
WO2023150592A2 (en) * | 2022-02-03 | 2023-08-10 | D.E. Shaw Research, Llc | N3-substituted uracil compounds as trpa1 inhibitors |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2797220A (en) * | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
NZ240644A (en) | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
WO1993016699A1 (en) | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
ATE230990T1 (de) | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
US6469017B1 (en) * | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
US5473070A (en) * | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
US6693105B1 (en) * | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
AU6702894A (en) | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
US6780865B1 (en) * | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
EP0746557A4 (de) * | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | Intrazellulärer signalübermittler |
US6103730A (en) * | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
CA2369981A1 (en) | 1999-04-09 | 2000-10-19 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
EP1377834A2 (de) | 2001-04-11 | 2004-01-07 | Glaxo Group Limited | Medikamente die modulatoren von hm74 und/oder hm74a activität sind |
EP1404675B1 (de) * | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
EP1338595B1 (de) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthin-Derivate als DPP-IV-Inhibitoren |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
GB0319124D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
DK1781657T3 (da) * | 2004-02-14 | 2013-06-10 | Glaxosmithkline Ip Dev Ltd | Medikamenter med hm74a-receptor aktivitet |
US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
EP1805180A1 (de) * | 2004-10-22 | 2007-07-11 | SmithKline Beecham Corporation | Xanthinderivate mit aktivität amhm74a-rezeptor |
WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
JP2008530074A (ja) * | 2005-02-14 | 2008-08-07 | スミスクライン・ビーチャム・コーポレイション | Hm74a受容体アゴニストとしてのアントラニル酸誘導体 |
NZ565494A (en) * | 2005-08-10 | 2011-06-30 | Glaxosmithkline Llc | Xanthine derivatives as selective HM74A agonists |
GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
RS53777B1 (en) | 2008-12-08 | 2015-06-30 | Glaxosmithkline Llc | 8-CHLORO-3-PENTYL-3,7-DIHYDRO-1H-PURIN-2,6-DION 2-AMINO-2- (HYDROXYMETHYL) -1,3-PROPANDIOL ANHYDRID FOR DISEASE TREATMENT |
-
2006
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 EP EP06763016A patent/EP1912991B1/de active Active
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 EP EP10172674A patent/EP2272848B1/de active Active
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 EP EP06776699A patent/EP1912992A1/de not_active Withdrawn
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en active Application Filing
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en active Application Filing
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Application Discontinuation
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Application Discontinuation
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
-
2008
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
- 2008-07-08 HK HK08107505.5A patent/HK1116779A1/xx not_active IP Right Cessation
-
2010
- 2010-12-27 HR HR20100725T patent/HRP20100725T1/hr unknown
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100725T1 (hr) | Derivati ksantina kao selektivni agonisti hm74a | |
JP2007522176A5 (de) | ||
AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
Ritter et al. | G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges | |
US9487508B2 (en) | SGC stimulators | |
RU2345067C2 (ru) | Ингибиторы дпп-iv | |
RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
JP2007502264A5 (de) | ||
RU2010132278A (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
EA200970726A1 (ru) | Твердый препарат, содержащий алоглиптин и пиоглитазон | |
JP2011508775A5 (de) | ||
JP2009102423A5 (de) | ||
MXPA06013251A (es) | Compuestos y composiciones de aril-cetona para suministrar agentes activos. | |
RU2019120203A (ru) | Новые соединения в качестве пептидных агонистов рецепторов glp1/глюкагона/gip | |
US20190142905A1 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
CN106748922A (zh) | 一类新型砜酸衍生物、其制备方法及其作为药物的用途 | |
HRP20130869T1 (hr) | 5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola | |
CN102812000A (zh) | Dp2拮抗剂及其用途 | |
Mathur et al. | Insight into structure activity relationship of DPP-4 inhibitors for development of antidiabetic agents | |
CN113072484A (zh) | 含有琥珀酸酯的磺胺苯甲酰胺类化合物及其制备方法与应用 | |
Humphries et al. | Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents | |
CN102949406B (zh) | 一种复方艾夫他滨药物组合物及其制备方法和用途 | |
JP2012511028A5 (de) | ||
RU2019112450A (ru) | Энантиомер замещенной фенилпропионовой кислоты и способ его получения, его композиция и применение | |
Kong et al. | Synthesis and biological evaluation of novel potent FFA1 agonists containing 2, 3-dihydrobenzo [b][1, 4] dioxine |